



PATENT
Docket No. 208.3A

1623
#17
Wilcom/1/-
fdr

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Henry A. Lardy, et al..)	Group Art Unit 1623
App. No.	:	09/675,323)	
Filed	:	September 28, 2000)	
For	:	THERAPEUTIC TREATMENT OF ANDROGEN RECEPTOR DRIVEN CONDITIONS)	
Examiner	:	E. Peselev)	

RECEIVED
MAY 05 2003
TECH CENTER 1600/2900

INFORMATION
DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Enclosed is form PTO-1449 (in duplicate) listing references (31), which are also enclosed.

Please charge any fees due or credit any overpayments to **Deposit Account No. 501536**.
A duplicate copy of this sheet is enclosed.

Respectfully submitted,

HOLLIS-EDEN PHARMACEUTICALS, INC.

Dated: April 29, 2003

Darryl
Heather L. Callahan
Mychan

By: Heather L. Callahan
Heather L. Callahan, Reg. No. 43,524
Hollis-Eden Pharmaceuticals, Inc.
4435 Eastgate Mall, Suite 400
San Diego, California, 92121
Telephone: (858) 587-9333
Customer No. 26,551



RECEIVED

MAY 05 2003

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Washington, D.C. 20231


CERTIFICATE OF MAILING BY FIRST-CLASS MAIL

Attorney Docket No. : 208.3A
Applicant(s) : Henry A. Lardy, et al.
Serial No. : 09/675,323
Filed : September 28, 2000
For : Therapeutic Treatment of Androgen Receptor
Driven Conditions
Attorney : Heather L. Callahan, Registration No. 43,524
Date of Deposit : April 29, 2003

I hereby certify that the accompanying

Information Disclosure Statement Transmittal (in duplicate); Form 1449 (in
duplicate), with attached references (31); and Return Postage Prepaid Postcard

are being deposited with the United States Postal Service First-Class Mail Post Office to
Addressee service, pursuant to 37 CFR § 1.8, on the date indicated above and are addressed to
the U.S. Patent and Trademark Office, P.O. Box 2327, Arlington, VA 22202, ATTN: Box DD.


Name: Sandy Beach